QIAGEN convened TB experts. Qiagen stock trades 1.07 percent higher.

Published on 10/19/2026 at 09:21 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue reached USD 535.04 million and adjusted EPS USD 0.62. Qiagen stock costs EUR 41.44 on October 19, 2026, 1.07 percent above Xetra close.

Qiagen's next reporting date

Qiagen convened tuberculosis experts on October 13, 2026, according to 6ix.
Second-quarter 2026 revenue was USD 535.04 million and adjusted diluted earnings per share were USD 0.62.
Qiagen stock trades at EUR 41.44 at 9:17 a.m. CEST at Lang & Schwarz on October 19, 2026, 1.07 percent above the Xetra close of October 16, 2026.

Pipette tropft klare Flüssigkeit in sterile 96-Well-Platte, klinisches Laborlicht — Qiagen N.V. (NL0012169213) Pipette tropft klare Flüssigkeit in sterile 96-Well-Platte im klinischen Labor, Illustration mit AI erstellt.

Qiagen N.V. (ISIN NL0015002SN0) was trading at EUR 41.44 at Lang & Schwarz on October 19, 2026 at 9:17 a.m. CEST, 1.07 percent above the Xetra close of October 16, 2026 at EUR 41.00. The company convened global tuberculosis experts on October 13, 2026, according to 6ix.

Tuberculosis event adds a public-health angle

The October 13 event placed tuberculosis testing and funding pressure alongside Qiagen's molecular diagnostics business. 6ix lists the event as Qiagen's latest news release and also records the company's September 28 FDA clearance for a QIAstat-Dx bloodstream infection panel.

The event matters because QuantiFERON testing was a key part of Qiagen's second-quarter operating picture. The company said QuantiFERON sales rose 1 percent at constant exchange rates in the second quarter of 2026, while lower US immigration testing demand constrained the result.

What does the next report test?

Qiagen reported USD 535.04 million of revenue in the second quarter of 2026, unchanged from the year-earlier quarter, while operating profit reached USD 132.40 million. Net income attributable to common shareholders was USD 103.40 million and diluted earnings per share were USD 0.50.

Adjusted diluted earnings per share came to USD 0.62, above the company's outlook for at least USD 0.60. Qiagen also reaffirmed full-year 2026 expectations for revenue growth of 1 to 2 percent at constant exchange rates and adjusted diluted earnings per share of at least USD 2.43.

Reporting date is the next catalyst

TickerLandia lists October 26, 2026 as the next quarterly-results date for Qiagen. That date gives investors a near-term test of whether the growth pillars can offset weaker instrument demand and the pressure on immigration-related testing.

Stock stays below its yearly high

Qiagen's Xetra range on October 16, 2026 ran from EUR 27.31 to EUR 47.16, putting the current Lang & Schwarz quote EUR 5.72 below that reported high. The stock's market picture therefore combines a modest daily premium with a wider distance from its annual peak.

Qiagen was trading at EUR 41.44 at Lang & Schwarz on October 19, 2026 at 9:17 a.m. CEST, 1.07 percent above the Xetra close of October 16, 2026 at EUR 41.00. The further course of trading is shown by the continuously updated real-time quote of Qiagen stock.